A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis

Phase 2 Completed 249 enrolled Evelo Biosciences, Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

This Phase 2 study has been designed to investigate the clinical safety and efficacy of EDP1815 and to identify an optimal dose in subjects with mild to moderate psoriasis.

Timeline

Start: 2020-09-21
Primary completion: 2021-07-02
Completion: 2021-12-06

Publications

Ehst BD, Strober B, Blauvelt A, Maslin D, Macaro D, Carpenter N, Bodmer M, McHale D. A randomized, double-blinded, phase 2 trial of EDP1815, an oral immunomodulatory preparation of Prevotella histicola, in adults with mild-to-moderate plaque psoriasis. Front Med (Lausanne). 2024 May 15;11:1292406. doi: 10.3389/fmed.2024.1292406. eCollection 2024.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	EDP1815	Other / unclassified	8e+10 cells	Oral
Subject	EDP1815	Other / unclassified	3.2e+11 cells	Oral
Subject	EDP1815	Other / unclassified	8e+11 cells	Oral

A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis

Summary

Timeline

Publications

Drugs

Indications